Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov;19(11):1545-1550.
doi: 10.1002/ejhf.829. Epub 2017 Sep 25.

The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

Anthony Mathur  1 , Roman Arnold  2 , Birgit Assmus  3 , Jozef Bartunek  4 , Ann Belmans  5 , Halvard Bönig  6 , Filippo Crea  7 , Stefanie Dimmeler  3 , Sheik Dowlut  1 , Francisco Fernández-Avilés  8 , Manuel Galiñanes  9 , David Garcia-Dorado  9 , Juha Hartikainen  10 , Jonathan Hill  11 , Annette Hogardt-Noll  12 , Christian Homsy  13 , Stefan Janssens  14 , Petr Kala  15 , Jens Kastrup  16 , John Martin  17 , Philippe Menasche  18 , Roman Miklik  15 , Abdul Mozid  19 , J Alberto San Román  2 , Ricardo Sanz-Ruiz  8 , Michal Tendera  20 , Wojtek Wojakowski  20 , Seppo Ylä-Herttuala  10 , Andreas Zeiher  3
Affiliations
Clinical Trial

The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: rationale and design of the BAMI trial

Anthony Mathur et al. Eur J Heart Fail. 2017 Nov.

Abstract

Over the past 13 years bone marrow-derived mononuclear cells (BM-MNCs) have been widely investigated for clinical efficacy in patients following acute myocardial infarction (AMI). These early phase II trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. The phase III BAMI trial has therefore been designed to demonstrate that intracoronary infusion of BM-MNCs is safe and will significantly reduce the time to first occurrence of all-cause death in patients with reduced left ventricular ejection fraction after successful reperfusion for ST-elevation AMI (powered with the aim of detecting a 25% reduction in all-cause mortality). This is a multinational, multicentre, randomized, open-label, controlled, parallel-group phase III study aiming to enrol approximately 3000 patients in 11 European countries with at least 17 sites. Eligible patients who have impaired left ventricular ejection (≤45%) following successful reperfusion for AMI will be randomized to treatment or control group in a 1:1 ratio. The treatment group will receive intracoronary infusion of BM-MNCs 2-8 days after successful reperfusion for AMI added on top of optimal standard of care. The control group will receive optimal standard of care. The primary endpoint is time from randomization to all-cause death. The BAMI trial is pivotal and the largest trial to date of BM-MNCs in patients with impaired left ventricular function following AMI. The aim of the trial is to provide a definitive answer as to whether BM-MNCs reduce all-cause mortality in this group of patients.

Trial registration: ClinicalTrials.gov NCT01569178.

Keywords: BAMI; Bone marrow-derived mononuclear cells; Cardiac regeneration; Cardiovascular disease; Cell therapy; Heart failure; Myocardial infarction.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow‐chart of t2c001 drug substance production. PBS, phosphate‐buffered saline.
Figure 2
Figure 2
BAMI study flowchart. AMI, acute myocardial infarction; BM‐MNC, bone marrow‐derived mononuclear cell; EF, ejection fraction.
See this image and copyright information in PMC

References

    1. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS‐AMI Trial Investigators . Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel‐eluting stents versus bare‐metal stents in acute myocardial infarction (HORIZONS‐AMI): final 3‐year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193–2204. - PubMed
    1. Setoguchi S, Glynn RJ, Avorn J, Mittleman MA, Levin R, Winkelmayer WC. Improvements in long‐term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10‐year trend analysis. J Am Coll Cardiol 2008;51:1247–1254. - PubMed
    1. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST‐elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006;367:579–588. - PubMed
    1. Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST‐segment elevation myocardial infarction: the HORIZONS‐AMI trial. Eur Heart J Acute Cardiovasc Care 2014;3:67–77. - PMC - PubMed
    1. Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, Mehran R, Stone GW. Incidence and predictors of heart failure following percutaneous coronary intervention in ST‐segment elevation myocardial infarction: the HORIZONS‐AMI trial. Am Heart J 2011;162:663–670. - PubMed

Publication types

Associated data